Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.

Clinical colorectal cancer - 1 Dec 2017

Costa Talita, Nuñez Jose, Felismino Tiago, Boente Leonardo, Mello Celso

Abstract excerpt

BACKGROUND: Treatment of metastatic colorectal adenocarcinoma (mCRC) has evolved, and survival is over 30 months in contemporary trials. Nevertheless, there is a paucity of effective regimes after the first or second-line treatment. Thus, reexposure to previously used drugs has become a treatment strategy for some patients. We aimed to evaluate the efficacy of retreatment with an oxaliplatin-containing regimen in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Liver Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Patient Selection

Share to Retreatment

Share to Survival Rate

Share to Treatment Failure

Source

Identifiers

PMID: 28392022
DOI: 10.1016/j.clcc.2017.03.002

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

REOX: Evaluation of the Efficacy of Retreatment With an Oxaliplatin-containing Regimen in Metastatic Colorectal Cancer: A Retrospective Single-center Study.PMID 28392022Read ↗

Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAFV600E mutation status.Semantic proximity Read ↗

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset.Semantic proximity Read ↗

Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.Semantic proximity Read ↗

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.Semantic proximity Read ↗

Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy.Semantic proximity Read ↗

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.Semantic proximity Read ↗

The Survival Impact of Fluoropyrimidine Metronomic Maintenance Therapy Following Adjuvant Oxaliplatin-based Chemotherapy in Patients with Stage III Colorectal Cancer after Radical Resection: Functional Roles of EGFR as a Potential PredictorSemantic proximity Read ↗

FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.Semantic proximity Read ↗

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Semantic proximity Read ↗

Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.Semantic proximity Read ↗

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.Semantic proximity Read ↗

Predictive Values of EGFR expression for the Fluoropyrimidine Metronomic Maintenance Therapy in Patients with Stage III Colorectal Cancer after Radical Resection and Adjuvant Oxaliplatin-Based ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.